Manufacturer record
Panacea Laboratories: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Panacea Laboratories (West Bengal) was declared Not of Standard Quality in March 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PL-182, Salbutamol Sulphate, I.P (Equivalent to salbutamol) -2mg Bromhexine Hydrochloride, IP-4mg Guaiphenesin, IP-100mg Menthol, IP-1mg (exp Aug 2027). CDL, Kolkata (CDSCO lab) found it not of standard quality: The sample does not conform to manufacturers specification with respect to the Assay of Bromhexine Hydrochloride. Listed in the March 2026 alert.
Records by type
1 record linked to Panacea Laboratories in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Salbutamol Sulphate, I.P (Equivalent to salbutamol) -2mg Bromhexine Hydrochloride, IP-4mg Guaiphenesin, IP-100mg Menthol, IP-1mg | Batch PL-182Mfg Sep 2025 · Exp Aug 2027 | The sample does not conform to manufacturers specification with respect to the Assay of Bromhexine Hydrochloride.Assay | CDL, KolkataCDSCO lab | Mar 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.